age-related macular degeneration, AMD, Diseases, genentech, lucentis, News, Research, wet AMD

ARVO 2018: Port Delivery System Designed to Reduce Burden of Lucentis Injections for Wet AMD

Originally published on this site - link to post

Dr. Christopher Brittain, Genentech medical director, discusses his company’s port delivery system, a tiny capsule implanted into the eye, for delivery of Lucentis® over a period of a few months. The device is currently in a Phase 2 clinical trial.

The image on the right shows the port implanted into an eye.

Leave a Comment

Your email address will not be published. Required fields are marked *

*